Admiral’s investments in data and proprietary technology have led to market-leading rates of underwriting for a maintained period of time.

Based on 9 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

In those two years, the admiral shares lost 6.4% annualized, trailing its typical large-growth category peer's 2.6% loss and well behind its prospectus Russell 1000 Growth Index's 0.6% gain.